A Qualitative Study of Increasing β-Blocker Use After Myocardial Infarction

Abstract
Randomized clinical trials have demonstrated the efficacy of β-blocker use in reducing mortality and future cardiac events after acute myocardial infarction (AMI).1 Based on substantial evidence, clinical practice guidelines for AMI published by the American College of Cardiology and the American Heart Association2 strongly recommend the use of β-blockers for secondary prevention after AMI.

This publication has 17 references indexed in Scilit: